Clearside Biomedical, Inc.CLSDNASDAQ
Loading
EPS Growth Under PressureDecelerating
Percentile Rank23
Year-over-Year Change
Year-over-year earnings per share growth rate
Percentile
P23
Within normal range
vs 5Y Ago
-0.5x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -31.03% |
| Q2 2025 | 47.27% |
| Q1 2025 | -14.23% |
| Q4 2024 | 3.70% |
| Q3 2024 | 0.00% |
| Q2 2024 | 41.18% |
| Q1 2024 | -119.64% |
| Q4 2023 | 48.40% |
| Q3 2023 | 0.00% |
| Q2 2023 | 0.00% |
| Q1 2023 | -7.14% |
| Q4 2022 | -7.69% |
| Q3 2022 | 0.00% |
| Q2 2022 | 0.00% |
| Q1 2022 | -141.94% |
| Q4 2021 | 477.13% |
| Q3 2021 | 25.27% |
| Q2 2021 | 15.38% |
| Q1 2021 | 7.14% |
| Q4 2020 | -170.27% |
| Q3 2020 | 60.15% |
| Q2 2020 | -100.00% |
| Q1 2020 | 10.96% |
| Q4 2019 | 57.06% |
| Q3 2019 | -13.33% |
| Q2 2019 | 66.67% |
| Q1 2019 | 33.82% |
| Q4 2018 | 9.33% |
| Q3 2018 | -15.38% |
| Q2 2018 | -4.84% |
| Q1 2018 | 4.62% |
| Q4 2017 | 9.72% |
| Q3 2017 | -33.33% |
| Q2 2017 | -31.71% |
| Q1 2017 | 8.89% |
| Q4 2016 | -60.71% |
| Q3 2016 | 54.84% |
| Q2 2016 | -82.35% |
| Q1 2016 | 19.05% |
| Q4 2015 | -50.00% |